Savara Inc. (NASDAQ:SVRA) Stock Short Interest Report for October

Savara Inc. (NASDAQ:SVRA) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 28,737,897 shares, a decline of 34.0% from the September 30th total of 43,563,969 shares. Approximately 14.8% of the shares of the company are short sold. Based on an average daily trading volume, of 2,349,629 shares, the days-to-cover ratio is presently 12.2 days.

Analyst Upgrades and Downgrades

SVRA has been the subject of a number of research analyst reports. Citigroup restated a “market outperform” rating on shares of Savara in a research note on Wednesday, October 7th. JPMorgan Chase & Co. initiated coverage on Savara in a research note on Wednesday, October 7th. They set an “overweight” rating and a $12.00 price target on the stock. Royal Bank Of Canada set a $10.00 price objective on Savara in a report on Wednesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Thursday, October 15th. Finally, Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.25.

Hedge Funds Weigh In On Savara

Several hedge funds and other institutional investors have recently made changes to their positions in SVRA. BlackRock Inc. purchased a new stake in shares of Savara during the second quarter worth approximately $76,966,000. Nantahala Capital Management LLC purchased a new position in Savara in the 2nd quarter valued at $42,977,150. Spruce Street Capital LP acquired a new stake in Savara during the 2nd quarter worth $21,267,868. ADAR1 Capital Management LLC acquired a new stake in Savara during the 2nd quarter worth $8,645,000. Finally, Algert Global LLC boosted its stake in Savara by 53.7% during the 2nd quarter. Algert Global LLC now owns 1,329,259 shares of the company’s stock worth $8,188,000 after purchasing an additional 464,645 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Price Performance

NASDAQ SVRA traded up $0.07 on Tuesday, hitting $4.80. The company had a trading volume of 233,724 shares, compared to its average volume of 1,735,780. Savara has a 12-month low of $3.86 and a 12-month high of $7.01. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The company’s fifty day moving average price is $5.06 and its 200-day moving average price is $5.39. The company has a market capitalization of $985.39 million, a PE ratio of -8.28 and a beta of 0.20.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). As a group, analysts predict that Savara will post -0.66 earnings per share for the current year.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s work is centered on conditions with significant unmet medical needs, particularly diseases involving impaired lung function and abnormal accumulation of material in the lungs.

Savara’s lead product candidate is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder in which surfactant accumulates in the airspaces and interferes with breathing.